Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
M&A activity
confidence 95%
filed 2026-07-06
EX-99.1
ING announced a strategic investment acquiring approximately 40% stake in Singular Bank, a leading Spanish wealth manager with €19 billion in client invested assets. The transaction represents a material acquisition of a significant ownership stake in an independent financial institution, fitting squarely within the M&A activity category. The press release explicitly describes this as a "strategic investment" and "acquisition of a stake," with closing expected in Q1 2027 subject to regulatory approvals, and CEO commentary emphasizing it as a key strategic move to accelerate growth in Private Banking and Wealth Management.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-06
EX-99.1
This press release announces the launch of Intermap's AI-enabled Orthorectification Service on the UP42 platform, a new commercial product offering that expands the company's role in the satellite imagery ecosystem. The disclosure describes a material operational and strategic development—the introduction of a scalable intelligence service leveraging the company's proprietary 3D terrain data—that would affect a reasonable investor's assessment of the company's growth prospects and market positioning in the expanding commercial space and Earth observation markets.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-06
Item 7.01
The filing discloses a scheduled earnings release announcement for PennantPark Floating Rate Capital Ltd.'s third fiscal quarter ended June 30, 2026, to be reported on August 10, 2026. The press release explicitly states the company "announced that it will report results for the third fiscal quarter ended June 30, 2026" and includes details of a conference call to discuss financial results. This is a material disclosure of quarterly earnings results, typical of Item 7.01 Regulation FD disclosures announcing earnings dates.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-06
Item 7.01
The filing discloses a press release announcing PennantPark Investment Corporation's scheduled earnings release for the third fiscal quarter ended June 30, 2026, with results to be reported on August 10, 2026, and a conference call scheduled for August 11, 2026. Although this is technically an announcement of when earnings will be released rather than the earnings themselves, the core disclosure is the earnings announcement, which is material to investors assessing the company's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-07-06
Item 8.01
The press release announces that Brookfield Asset Management will host a second quarter 2026 results conference call on August 5, 2026, with results to be released that morning prior to 7:00 a.m. ET. This is a standard earnings announcement disclosing the timing and logistics for the release of quarterly financial results, which is material to investors assessing the company's financial performance.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-07-06
EX-99.1
The exhibit discloses material equity issuance activity under the Company's at-the-market (ATM) program, which generated approximately US$2.1 million in gross proceeds through the issuance of 3,009,295 Common Shares during Q2 2026 at a weighted average price of US$0.68 per share. The ATM program itself is authorized for up to US$25 million. This represents a dilutive equity issuance that would materially affect a reasonable investor's assessment of share dilution and capital structure. While the exhibit also mentions employee share purchase and director DSU grants, the primary material disclosure is the ATM equity offering activity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-06
EX-99.1
This press release discloses material clinical and pipeline progress across Molecular Partners' Radio-DARPin therapeutic program, including: ongoing Phase 1/2a dosing of MP0712 (DLL3-targeted, 212Pb-based) with initial data expected within months; initiation of compassionate care work in South Africa with MP0714 (225Ac-loaded DLL3 Radio-DARPin); planned first-in-human imaging for MP0726 (MSLN-targeted) in H2 2026; and two planned INDs in 2027. While not a discrete M&A, financing, or governance event, these clinical milestones and pipeline expansions materially advance the company's drug development strategy and would affect a reasonable investor's assessment of near-term catalysts and long-term value creation.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-06
EX-99.1
ZIM discloses an update on its "previously announced merger agreement with Hapag-Lloyd" and states the company "continues to act in accordance with the agreement and in ongoing collaboration with the relevant state authorities as part of the regulatory review process." This is a material acquisition/merger activity (Item 1.01 or 2.01 equivalent) that would materially affect a reasonable investor's assessment of the registrant's future, even though the update itself is procedural in nature.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 92%
filed 2026-07-06
The 6-K discloses results of Tower Semiconductor's annual general meeting held July 2, 2026, where shareholders voted on multiple proposals. The filing explicitly states that "all proposals were approved at the meeting by the requisite majority" except Proposal 3 (amended compensation policy), which failed. This is a direct shareholder vote result disclosure, matching the shareholder_vote_results event type. The failure of the compensation policy proposal is material to investors assessing governance and executive compensation practices.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-06
EX-99.1
The exhibit discloses the appointment of Yoav Har-Even as an independent director of Innoviz Technologies Ltd. effective July 5, 2026, to fill a newly vacant seat. This is a clear executive/governance appointment event. While the filing also mentions James Sheridan's resignation, the principal disclosed action is the appointment of a new director with significant qualifications (former CEO of Rafael Advanced Defense Systems, retired Major General). Board composition changes affecting independent director status are material to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
Item 3.02
IGC Pharma issued 4,274,853 shares of common stock to executive officers (CEO Ram Mukunda and CFO Claudia Grimaldi) in a debt-for-equity conversion, canceling $1,154,210 in outstanding obligations. The unregistered private placement under Section 4(a)(2) of the Securities Act represents a material dilutive equity transaction affecting shareholder ownership structure and executive compensation.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-06
Item 2.03
UY Scuti Acquisition Corp. created a direct financial obligation by borrowing $450,000 from Isdera HK Limited (an affiliate of Isdera Group) to extend its trust account deadline, with the Company expecting to issue a promissory note to the lender.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-06
Item 8.01
The Company extended the deadline to consummate an initial business combination with Isdera Group Limited following a deposit to the Trust Account, with a registration statement to be filed in connection with the pending merger transaction.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-06
The filing discloses issuance of 1,645,353 restricted shares totaling ¥10.98 billion to directors, corporate executive officers, and subsidiary executives under SMFG's stock compensation plans. This is a material compensatory arrangement involving equity grants with performance conditions and vesting schedules, filed pursuant to Japanese securities law requirements and incorporated by reference into SMFG's Form F-3 registration statement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
Item 1.01
Scilex entered into a binding term sheet with iHolding Group LLP for a $100 million strategic investment through the private placement of approximately 6.67 million newly issued shares of common stock at $15.00 per share, subject to customary closing conditions including stockholder approval and regulatory approvals.
View raw filing on EDGAR →
8-K
Governance Other
confidence 82%
filed 2026-07-06
Item 5.03
USA Compression Partners, LP redomiciled from Delaware to Texas on July 6, 2026, pursuant to board and Conflicts Committee approval. The conversion materially modified unitholder rights, fiduciary duty protections, liability limitations, distribution restrictions, and forum selection provisions under the Texas Business Organizations Code versus Delaware law, representing a material governance restructuring affecting investor protections and economic interests.
View raw filing on EDGAR →
8-K
Legal Other
confidence 85%
filed 2026-07-06
Item 8.01
Invivyd received a Notice of Termination of the Emergency Use Authorization (EUA) for PEMGARDA from the FDA, effective June 29, 2027, following HHS's announcement of termination of the COVID-19 EUA declaration. This is a material regulatory event that eliminates the company's primary authorized product and revenue source, but it is fundamentally a regulatory/legal matter rather than a financial restatement, going-concern issue, or other specific category. The company is in dialogue with the FDA regarding next steps, including potential Biologics License Application (BLA) submission, but the immediate event is the loss of regulatory authorization.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-07-06
Item 8.01
Strategy Inc. disclosed an $8.32 billion loss on digital assets in Q2 2026, including a significant unrealized loss requiring a full valuation allowance against deferred tax benefits. The disclosure also covers the company's bitcoin monetization strategy to fund its USD reserve.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-06
Item 8.01
Broadcom and Apple have entered into new multi-year long-term agreements for Broadcom to develop and supply custom ASIC silicon products through 2031, representing an expansion of their existing technology collaboration. This is a material strategic partnership and supply agreement that would affect investor assessment of Broadcom's revenue visibility and competitive positioning, but does not fit the specific categories of M&A activity, debt issuance, or other defined event types—making it an operational/strategic business event.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-06
Item 2.01
CoreCivic completed the sale of two detention facilities (California City Detention Facility and Otay Mesa Detention Center) to the U.S. Department of Homeland Security for an aggregate gross sales price of $1.5 billion on July 2, 2026, with net proceeds of approximately $1.1 billion after taxes and transaction expenses. The company intends to use proceeds to repay debt and pursue growth opportunities. This is a material disposition of significant assets representing a substantial portion of the company's real estate portfolio.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 1.01
Corbus Pharmaceuticals appointed Leonardo Viana Nicacio, M.D. as Chief Medical Officer, effective August 3, 2026, under a two-year employment agreement. Dr. Nicacio brings 20+ years of pharmaceutical development experience, including pivotal work on TIVDAK®, and expertise in ADCs and HPV-driven oncology directly aligned with the company's strategic priorities as it approaches initiation of the TEMPO-1 registrational study. The appointment includes material inducement equity awards of $2.1 million.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-06
Item 2.01
Middleby completed a spin-off of its Food Processing business as Midera Food Processing, Inc. on July 6, 2026, distributing 100% of Midera common stock to shareholders on a pro rata basis. Midera began trading on Nasdaq under ticker 'MFP' on July 7, 2026, representing a material change of control and disposition of a significant business segment.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-06
Item 5.02
Three executives departed from Middleby effective upon completion of the Midera spin-off: directors Robert A. Nerbonne and Cathy T. McCarthy resigned from the Board to join Midera's board, and Matthew R. Fuchsen resigned as Chief Development Officer to become Midera's Chief Strategy Officer.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-06
Item 1.01
Midera Food Processing completed its spin-off from The Middleby Corporation on July 6, 2026, with 100% of Midera's outstanding shares distributed pro rata to Middleby stockholders. Midera commenced independent public trading on Nasdaq under ticker 'MFP' on July 7, 2026, governed by multiple definitive agreements including a Separation and Distribution Agreement, Tax Matters Agreement, Employee Matters Agreement, Intellectual Property Matters Agreement, and Transition Services Agreement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Effective immediately prior to the spin-off consummation, Midera appointed a complete board of directors (8 members) and executive leadership team, including Mark M. Salman as CEO, Amy A. Campbell as CFO, Mark S. Bowie as COO, and Matthew R. Fuchsen as Chief Strategy Officer.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-06
EX-99.1
MindWalk announced its inclusion in the Russell 3000E Index effective June 26, 2026, as part of FTSE Russell's semi-annual reconstitution. While index inclusion is primarily a market-visibility and operational milestone rather than a discrete financial or governance event, it is material because it expands institutional investment eligibility and access to approximately $12.2 trillion in benchmarked assets, directly affecting the company's capital-market positioning and liquidity profile. This is an operational/strategic milestone that would affect a reasonable investor's assessment of the registrant's market accessibility.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-07-06
EX-99.1
Rogers Communications has signed an agreement to acquire the remaining 25% ownership stake in Maple Leaf Sports & Entertainment (MLSE) from Kilmer Sports Inc. for C$4.35 billion, increasing Rogers' ownership to 100%. This is a material acquisition transaction that would significantly affect investor assessment of the registrant's capital allocation, strategic direction, and financial position. The transaction is subject to league approvals and expected to close in Q4 2026.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-06
Item 8.01
The board of trustees declared a dividend of $0.625 per common share payable on August 14, 2026, to shareholders of record as of June 30, 2026. The disclosure explicitly states the dividend amount, payment date, and record date, with options for reinvestment or cash payment. This is a routine but material dividend distribution to shareholders.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-06
EX-99.1
This news release announces the closing of an acquisition by Cameco and Orano of TEPCO Resources Inc.'s 5% participating interest in the Cigar Lake Joint Venture. The transaction materially increases Cameco's ownership stake in the Cigar Lake uranium mine from approximately 54.5% to 57.418%, a significant increase in a material asset. This is a completed material acquisition that would affect a reasonable investor's assessment of Cameco's asset base and operational control.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 75%
filed 2026-07-06
The 6-K furnishes an "Amended and Restated Credit Agreement, dated as of June 24, 2026" as Exhibit 99.1. An amendment and restatement of a credit facility constitutes a material modification to the registrant's direct financial obligations. While the exhibit itself is not provided in the body text, the disclosure of a restated credit agreement is a debt-related event that would affect a reasonable investor's assessment of the registrant's capital structure and financing arrangements.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-06
Item 8.01
The filing discloses the declaration of June 2026 dividends for the Fund's common shares, with Class I shares receiving $0.1887 per share (9.00% annualized distribution yield), payable on or about July 24, 2026. This is a routine but material dividend distribution disclosure typical of closed-end funds, filed under Item 8.01 (Other Events).
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-06
Item 7.01
The board of directors declared a distribution of $0.42 per share payable to shareholders of record, with cash payment or reinvestment options available. This is a clear dividend or distribution declaration to shareholders, which is a material event affecting investor returns and capital allocation decisions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 8.01
Ouster completed a registered public offering of 3,621,876 shares of common stock at $55.22 per share, raising approximately $191.9 million in net proceeds. This is a material equity issuance disclosed under Item 8.01 that dilutes existing shareholders and represents a significant capital-raising event for the company.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 99%
filed 2026-07-06
Item 2.03
Extra Space Storage LP completed an underwritten public offering of $550 million in 4.900% Senior Notes due 2032, creating a material direct financial obligation with specified terms and restrictive covenants.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-06
Item 5.07
Achieve Life Sciences held an Annual Meeting of security holders at which stockholders voted on four matters: election of nine directors, ratification of PricewaterhouseCoopers LLP as independent auditor, a non-binding advisory vote on named executive officer compensation, and approval of a Certificate of Amendment to increase authorized common shares from 150 million to 300 million. All matters were approved with certified vote tallies disclosed.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 80%
filed 2026-07-06
Item 1.01
AGENUS extended the maturity of $5.09 million in senior subordinated notes from June 20, 2026 to February 18, 2027, and issued warrants to purchase 221,525 shares of common stock as part of a material restructuring of its financial obligations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-06
Item 3.02
AGENUS issued unregistered warrants to purchase 221,525 shares of common stock, representing a dilutive equity issuance to existing shareholders.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-06
The 6-K discloses completion of a redomiciliation and reorganization whereby Marex Group Limited (Bermuda) became the parent holding company of Marex Group plc (UK) through a statutory scheme of arrangement approved by shareholders on May 21, 2026 and the High Court on June 26, 2026, effective July 1, 2026. This constitutes a material change of control and corporate restructuring. The filing also documents New Marex's assumption of all outstanding debt obligations ($1.6 billion in senior notes, subordinated notes, and contingent capital securities) as successor issuer, which is integral to the reorganization transaction.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-06
Item 7.01
The filing discloses an announcement of the Company's second quarter 2026 financial results to be released on August 6, 2026, with a conference call scheduled for August 7, 2026. The press release explicitly states "Morgan Stanley Direct Lending Fund Announces Second Quarter 2026 Earnings Release and Conference Call," which is a standard earnings announcement. This is material to investors as it provides notice of when quarterly financial results will be disclosed.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-06
Item 5.02
The filing discloses both a director resignation (Dr. Jovan-Embiricos) and the election of a new director (Laurie Keating to the Board and Audit Committee, effective August 1, 2026). While both events occur, the principal action emphasized in the disclosure is the appointment of Ms. Keating, including detailed compensation terms (18,000 option grant, $40,000 annual cash, $7,500 Audit Committee fee). Director appointments are material governance events affecting board composition and oversight.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-07-06
Item 1.01
Fortress Net Lease REIT entered into a New Lender Joinder Agreement that increases the aggregate principal amount of its Credit Facilities from $1,800,000,000 to $1,900,000,000, including increases to both the Revolving Credit Facility (from $1,475,000,000 to $1,545,000,000) and the Term Loan Facility (from $325,000,000 to $355,000,000).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
Warburg Pincus Access Fund sold unregistered limited partnership units totaling $11.1 million to third-party investors on June 1, 2026, pursuant to Section 4(a)(2) and Regulation D exemptions, representing a significant capital raise and expansion of the Fund's investor base.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-06
Item 2.02
RxSight issued a press release on July 6, 2026 announcing preliminary unaudited second quarter 2026 financial results, including total company revenue of approximately $32–$34 million, LAL unit sales of 24,917 units, and cash position of approximately $209 million. The filing is disclosed under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes updated 2026 full-year guidance ($140–$160 million revenue) and gross margin expectations, making it a material financial results announcement.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-06
Item 1.01
RxSight entered into a material License, Collaboration and Development Agreement with Alcon on June 30, 2026, granting Alcon a non-exclusive, worldwide, royalty-bearing license to develop and commercialize light-adjustable versions of Alcon's simultaneous vision intraocular lenses using RxSight's LAL technology. The agreement provides RxSight with a $60 million upfront payment, up to $140 million in additional milestone payments, and 30% royalties on net sales, constituting a significant strategic collaboration that materially affects RxSight's revenue prospects and market position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
The filing discloses an unregistered sale of 1,873,541.8118 common shares for $47.3 million in aggregate consideration under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive equity issuance by a REIT in a continuous private offering, exempt from registration. The magnitude ($47.3M) and share count are material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-06
Item 8.01
The disclosure describes the entry into an underwriting agreement for a $500 million public offering of 4.950% Senior Notes due 2032, fully guaranteed by the Company and its subsidiaries. This is a material creation of a direct financial obligation under Item 8.01 (Other Events), with proceeds intended for general corporate purposes and potential debt repayment. The size, terms, and guaranteed structure make this a clear debt issuance event.
View raw filing on EDGAR →
8-K
Governance Other
confidence 65%
filed 2026-07-06
Item 5.03
Dell Technologies amended its bylaws to elect governance under Texas Business Organizations Code Section 21.373, which imposes heightened shareholder proposal thresholds including a minimum $1M market value or 3% ownership requirement, a six-month holding period, and a 67% solicitation requirement. This material modification to security holder rights affects investor assessment of voting power and shareholder proposal mechanisms.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-06
EX-99.1
Wallbox received a NYSE notice on February 12, 2026 for non-compliance with Section 802.01B regarding average global market capitalization and stockholders' equity. The NYSE has now accepted the Company's compliance plan, granting an 18-month cure period to achieve either $50 million in stockholders' equity or $50 million average market capitalization. This is a material delisting-risk disclosure: the Company faces potential suspension or delisting if it fails to meet the plan milestones, and the announcement explicitly addresses the NYSE's continued listing standards and the conditional nature of ongoing listing.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-06
Item 5.02
Jesse Coury resigned as Chief Financial Officer of Greystone Housing Impact Investors LP, the principal disclosed action. While the filing also describes a post-departure contractor agreement at $300/hour through September 30, 2026, the core event is the CFO's departure. The departure of a named executive officer in a financial leadership role is material to investors assessing management continuity and operational risk.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-07-06
Item 1.01
Targa Resources entered into a Seventeenth Amendment to its Receivables Purchase Agreement on July 1, 2026, extending the Facility Termination Date to July 30, 2027 and establishing a new uncommitted $200 million line. With approximately $451 million in outstanding trade receivable purchases, this amendment materially modifies the company's financing structure and credit facility. While this is technically an amendment to an existing securitization facility rather than a new debt issuance, it creates new financial obligations and extends the company's access to capital, which falls within the debt_issuance category as it represents a material creation or amendment of a direct financial obligation.
View raw filing on EDGAR →